Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $42.82M by Medicaid between Jan 2018 and Dec 2024, across 101 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
CHARLOTTE, NC 28262
CHARLOTTE, NC 28262
33aNPI1346297892assigned 05/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$42.82M
24GClaims610,867
24DCodes billed101
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#11 of 92
Median peer was paid$11.47M
This provider vs. median3.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 73,079 | $3.63M | |
| 2019 | 71,573 | $3.90M | |
| 2020 | 47,976 | $2.00M | |
| 2021 | 76,902 | $4.52M | |
| 2022 | 90,245 | $7.51M | |
| 2023 | 115,043 | $9.97M | |
| 2024incomplete | 136,049 | $11.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 76,253 | 71,240 | $15.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 67,162 | 61,959 | $13.14M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 21,595 | 19,867 | $4.22M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 7.8% | 20,289 | 18,968 | $3.36M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.7% | 719 | 688 | $1.17M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 20,517 | 18,693 | $636K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 21,431 | 20,113 | $629K |
| 80053 | Comprehensive metabolic panel | <1% | 39,198 | 35,705 | $404K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,213 | 41,210 | $367K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,568 | 21,747 | $363K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 6,604 | 6,160 | $306K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,862 | 3,495 | $304K |
89 more codes
| J3490 | Unclassified drugs | <1% | 64,241 | $248K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,325 | $211K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 514 | $199K |
| 81025 | <1% | 25,895 | $197K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 39 | $79K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 412 | $78K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,924 | $75K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,795 | $72K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,543 | $69K |
| 84484 | <1% | 7,656 | $67K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 429 | $67K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 36,071 | $66K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,403 | $62K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,403 | $61K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,292 | $58K |
| 83690 | <1% | 7,424 | $54K | |
| 81001 | <1% | 12,718 | $51K | |
| 0002A | <1% | 804 | $45K | |
| 0001A | <1% | 745 | $41K | |
| G0378 | Hospital observation service, per hour | <1% | 223 | $40K |
| 87430 | <1% | 2,048 | $34K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,928 | $29K |
| 87070 | <1% | 1,820 | $25K | |
| 85027 | <1% | 3,500 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,966 | $18K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 547 | $17K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,256 | $17K |
| 71045 | Radiologic examination, chest; single view | <1% | 798 | $17K |
| 81003 | <1% | 5,533 | $17K | |
| 81002 | <1% | 5,235 | $16K | |
| 81000 | <1% | 5,204 | $15K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 890 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,410 | $13K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 29 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 390 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,625 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,037 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 352 | $8K |
| 87210 | <1% | 1,625 | $6K | |
| 77336 | <1% | 91 | $5K | |
| 83735 | <1% | 553 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,073 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 241 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,176 | $3K |
| 84702 | <1% | 295 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,027 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,165 | $2K |
| 88304 | <1% | 31 | $2K | |
| 83880 | <1% | 70 | $2K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,547 | $2K |
| 77334 | <1% | 14 | $1K | |
| 83605 | <1% | 127 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 46 | $1K |
| 87081 | <1% | 162 | $1K | |
| 20610 | <1% | 13 | $1K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 703 | $894.01 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 379 | $862.31 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 43 | $636.37 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,155 | $578.19 |
| 80143 | <1% | 14 | $484.68 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 154 | $470.41 |
| 96376 | <1% | 113 | $461.67 | |
| 95800 | <1% | 12 | $447.08 | |
| 97597 | <1% | 20 | $426.92 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 681 | $319.65 |
| 80179 | <1% | 13 | $303.91 | |
| 85379 | <1% | 26 | $298.65 | |
| 87147 | <1% | 32 | $296.37 | |
| 99199 | Unlisted special service, procedure or report | <1% | 52 | $270.00 |
| 82803 | <1% | 14 | $265.52 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 117 | $251.44 |
| 97802 | <1% | 14 | $212.34 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $176.50 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $167.55 |
| 82962 | <1% | 65 | $144.86 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 78 | $100.91 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 38 | $81.64 |
| 94760 | <1% | 16 | $72.01 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 40 | $55.23 |
| 81015 | <1% | 15 | $51.38 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 26 | $37.13 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 46 | $34.74 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 27 | $30.54 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 17 | $26.89 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 13 | $23.64 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 12 | $20.77 |
| A9270 | Non-covered item or service | <1% | 1,255 | $0.17 |
| 91300 | 0% | 1,531 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.